Asterios Karagiannis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7907553/publications.pdf

Version: 2024-02-01

114 papers	2,562 citations	304368 22 h-index	214527 47 g-index
114 all docs	114 docs citations	114 times ranked	3898 citing authors

#	Article	IF	Citations
1	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
2	Gonadal dysfunction in systemic diseases. European Journal of Endocrinology, 2005, 152, 501-513.	1.9	187
3	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	1.5	144
4	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World Journal of Gastroenterology, 2015, 21, 7860.	1.4	130
5	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology, 2015, 21, 6820-6834.	1.4	120
6	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. Circulation Journal, 2007, 71, 1120-1127.	0.7	119
7	Health Benefits of the Mediterranean Diet. Angiology, 2015, 66, 304-318.	0.8	117
8	Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy, 2008, 9, 509-515.	0.9	115
9	Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer, 2007, 14, 935-956.	1.6	114
10	Contrast-Induced Nephropathy. Angiology, 2015, 66, 508-513.	0.8	96
11	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. Current Vascular Pharmacology, 2018, 16, 219-227.	0.8	87
12	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. Journal of the American Society of Hypertension, 2014, 8, 74-82.	2.3	75
13	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Current Vascular Pharmacology, 2018, 16, 246-253.	0.8	69
14	Nonalcoholic fatty liver disease and statins. Metabolism: Clinical and Experimental, 2015, 64, 1215-1223.	1.5	68
15	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology, 2018, 16, 130-142.	0.8	54
16	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension, 2021, 39, 749-758.	0.3	38
17	Is There an Association Between Inflammatory Bowel Diseases and Carotid Intima-media Thickness? Preliminary Data. Angiology, 2014, 65, 543-550.	0.8	30
18	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	1.8	29

#	Article	IF	Citations
19	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. Neurological Research, 2010, 32, 326-331.	0.6	26
20	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
21	The role of reninâ€“angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets, 2007, 11, 191-205.	1.5	24
22	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocrine-Related Cancer, 2008, 15, 693-700.	1.6	24
23	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24
24	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. Maturitas, 2018, 108, 45-52.	1.0	23
25	The Unilateral Measurement of Blood Pressure May Mask the Diagnosis or Delay the Effective Treatment of Hypertension. Angiology, 2005, 56, 565-569.	0.8	22
26	Lack of an Association between Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Ischaemic Stroke. European Neurology, 2004, 51, 148-152.	0.6	21
27	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology, 2021, 40, 4671-4674.	1.0	21
28	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 936-944.	0.6	20
29	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. Arthritis Research and Therapy, 2019, 21, 253.	1.6	18
30	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovascular Medicine Journal, 2014, 8, 55-60.	0.6	18
31	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. Hypertension Research, 2021, 44, 179-187.	1.5	17
32	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16
33	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry, 2020, 27, 6682-6702.	1.2	16
34	Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 139-146.	0.2	16
35	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. Open Cardiovascular Medicine Journal, 2009, 3, 26-34.	0.6	16
36	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 142-145.	1.2	15

#	Article	IF	Citations
37	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry, 2019, 11, 1285-1303.	1.1	15
38	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Current Pharmaceutical Design, 2017, 23, 1510-1521.	0.9	15
39	Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes and Endocrinology,the, 2017, 5, 329-330.	5.5	14
40	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. Current Vascular Pharmacology, 2010, 8, 792-803.	0.8	13
41	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. Lancet Diabetes and Endocrinology,the, 2014, 2, 362-363.	5.5	13
42	Renovascular Hypertension: Novel Insights. Current Hypertension Reviews, 2020, 16, 24-29.	0.5	13
43	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. Current Vascular Pharmacology, 2018, 16, 214-218.	0.8	13
44	Treatment of primary aldosteronism: Where are we now?. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 15-20.	2.6	12
45	Arterial Stiffness and Emerging Biomarkers. Angiology, 2015, 66, 901-903.	0.8	12
46	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. Microcirculation, 2021, 28, e12665.	1.0	12
47	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. Clinical Rheumatology, 2021, 40, 4957-4968.	1.0	12
48	Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?. Current Pharmaceutical Design, 2007, 13, 229-239.	0.9	11
49	Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. Kidney and Blood Pressure Research, 2019, 44, 679-689.	0.9	11
50	Medical studentsâ€™ satisfaction with the Applied Basic Clinical Seminar with Scenarios for Students, a novel simulation-based learning method in Greece. Journal of Educational Evaluation for Health Professions, 2016, 13, 13.	5.9	11
51	Statins and non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 241-242.	1.8	10
52	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. Journal of Clinical Hypertension, 2018, 20, 942-948.	1.0	10
53	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment, 2013, 2, 67-71.	1.1	9
54	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9

#	Article	IF	Citations
55	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
56	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. Current Vascular Pharmacology, 2018, 16, 393-400.	0.8	9
57	Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?. Current Vascular Pharmacology, 2019, 18, 38-42.	0.8	9
58	Subclinical Cushing's syndrome and cardiovascular disease. Lancet Diabetes and Endocrinology,the, 2014, 2, 361.	5.5	8
59	Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. British Journal of Clinical Pharmacology, 2017, 83, 742-750.	1.1	8
60	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. Rheumatology International, 2020, 40, 1997-2004.	1.5	8
61	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. Hormones, 2022, 21, 91-101.	0.9	8
62	Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Vascular Medicine, 2022, 27, 433-439.	0.8	8
63	Antihypertensive therapy in acute ischemic stroke: where do we stand?. Journal of Human Hypertension, 2018, 32, 799-807.	1.0	7
64	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension, 2021, 34, 404-413.	1.0	7
65	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300.	0.9	7
66	Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease. Vascular Medicine, 2004, 9, 189-192.	0.8	6
67	Are Patients With Inflammatory Bowel Diseases at Increased Risk for Cardiovascular Disease?. Clinical Gastroenterology and Hepatology, 2014, 12, 2134-2135.	2.4	6
68	Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke. International Journal of Hypertension, 2019, 2019, 1-9.	0.5	6
69	Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1686-1694.	1.1	6
70	Arterial adaptations in athletes of dynamic and static sports disciplines â€“ a pilot study. Clinical Physiology and Functional Imaging, 2019, 39, 183-191.	0.5	6
71	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Current Pharmaceutical Design, 2017, 23, 1477-1483.	0.9	6
72	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. Open Cardiovascular Medicine Journal, 2016, 10, 64-68.	0.6	6

#	Article	IF	Citations
73	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. Journal of Sexual Medicine, 2019, 16, 1199-1211.	0.3	5
74	Multimodal Treatment of Homozygous Familial Hypercholesterolemia. Current Pharmaceutical Design, 2019, 24, 3616-3621.	0.9	5
75	Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study. CKJ: Clinical Kidney Journal, 2021, 14, 1165-1172.	1.4	5
76	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2021, 159, 143-146.	0.7	5
77	Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay. Angiology, 2018, 69, 745-748.	0.8	4
78	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and nonâ€diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
79	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Current Vascular Pharmacology, 2018, 16, 276-288.	0.8	4
80	Peripheral artery disease in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 912.	1.2	3
81	Acute Coronary Syndrome in Patients With Inflammatory Bowel Diseases: The Plaque and the Thrombus. Angiology, 2017, 68, 843-844.	0.8	3
82	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. Hormones, 2018, 17, 83-95.	0.9	3
83	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
84	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. Clinical Lipidology, 2016, 11, 2-5.	0.4	3
85	Effects of Fosinopril on Renal Function in Patients with Mild to Moderate Essential Hypertension. Clinical Drug Investigation, 1996, 12, 251-258.	1.1	2
86	Subclinical target organ damage in primary aldosteronism. Journal of Hypertension, 2018, 36, 701.	0.3	2
87	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. Journal of Clinical Hypertension, 2018, 20, 634-636.	1.0	2
88	Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options. Current Vascular Pharmacology, 2022, 20, 52-61.	0.8	2
89	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120.	0.7	2
90	Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 170-174.	1.3	2

#	Article	IF	Citations
91	Off target effects of statins shape total mortality?. Journal of Drug Assessment, 2016, 5, 4-5.	1.1	1
92	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1295-1296.	6.3	1
93	Determinants of pulse wave velocity index and potential implementations. Journal of Clinical Hypertension, 2019, 21, 1493-1495.	1.0	1
94	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 239-240.	0.4	1
95	SO036THE EFFECT OF DAPAGLIFLOZIN ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
96	Ertugliflozin + metformin as a treatment option for type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2105-2111.	0.9	1
97	Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. Current Pharmaceutical Design, 2019, 24, 5542-5547.	0.9	1
98	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2022, 167, 165-167.	0.7	1
99	Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic Journal of Cardiology, 2006, 47, 298-307.	0.4	1
100	â€œWhich one should I choose, a glucagon-like peptide-1 receptor agonist or a sodiumâ˜’glucose cotransporter 2 inhibitor? Or maybe both?â€• European Journal of Internal Medicine, 2022, 98, 125-127.	1.0	1
101	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiologia Polska, 2022, 80, 696-698.	0.3	1
102	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease. American Journal of Cardiology, 2022, 174, 188-189.	0.7	1
103	Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review. Diseases (Basel, Switzerland), 2013, 1, 51-72.	1.0	0
104	Cardiovascular Risk in Middle East Populations. Angiology, 2015, 66, 801-802.	0.8	0
105	Fitness: The â€œSecretâ€•of Vascular Youth. Journal of Clinical Hypertension, 2016, 18, 290-291.	1.0	0
106	PATHWAY-2: spironolactone for resistant hypertension. Lancet, The, 2016, 387, 1371-1372.	6.3	0
107	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt â€“ results from the GUARD study. Curr Med Res Opin 2017;33:797-801. Current Medical Research and Opinion, 2017, 33, 2261-2262.	0.9	0
108	Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J etÂal. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol . 2016;10(5):1091-1097. Journal of Clinical Lipidology, 2017, 11, 306-307.	0.6	0

#	Article	IF	Citations
109	FP516THE RENOPROTECTIVE EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
110	P0156SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
111	P0763A COMPARATIVE STUDY OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
112	MO642DAPAGLIFLOZIN HAS NO IMPACT ON SHORT-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
113	Colchicine for the prevention of COVID-19 â€œhardâ€•outcomes: All that glitters is not gold. European Journal of Internal Medicine, 2022, 97, 108-109.	1.0	0
114	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients withÂtype 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. Kardiologia Polska, 2022, 80, 80-82.	0.3	0